Dr Alex Rothman (from the Department of Infection, Immunity & Cardiovascular Disease) has been awarded a Wellcome Clinical Career Development Fellowship to pursue his aim to establish SMURF-1 inhibition as a novel anti proliferative therapy in pulmonary arterial hypertension. Alex will spend time undertaking his research in Sheffield, Cambridge and at Novartis in Boston, Massachusetts, USA.
The Fellowship will start in November 2017 and run until November 2022. The award of £760,409 (funder contribution £460,409) will build on the excellent reputation in Sheffield for research into pulmonary arterial hypertension.
One of the reviewers assessed his application as follows, “This is an amazing candidate studying a wholly novel pathway in a disease where there is significant need for major advancement. Dr Rothman will be working with the top mentors in the world in basic science, clinical research and pharmaceutical development”
Dr Alex Rothman said:
I am delighted to have the opportunity to continue my work developing new treatments for patients with PAH and am very grateful to the patients, the team of researchers and the funders who have provided great support to these studies.
Professor Sheila Francis (Head of Department) said “The whole Department is extremely proud of Alex and what he has achieved. It has taken grit, hard work, determination and resilience. I have no doubt that Alex will be at the forefront of developing new treatments for pulmonary arterial hypertension in the future.”
Congratulations Alex on this excellent achievement!